

Special Issue

Next-Generation Platforms for Vaccine Design and Immune Evaluation

Message from the Guest Editors

The rapid growth of vaccine technologies, accelerated by the COVID-19 pandemic, has introduced powerful platforms such as mRNA vaccines, viral vectors, peptide constructs, and nanoparticle systems. Alongside these, computational tools, bioinformatics, and AI are reshaping vaccine discovery by improving design and immune response prediction. However, challenges remain, including boosting immunogenicity, achieving long-term protection, and understanding host–pathogen interactions. Combining innovative platforms with in silico modeling, omics approaches, and clinical validation offers new solutions. This Special Issue welcomes contributions on next-generation vaccine design, AI-driven development, delivery technologies, systems immunology, and translational perspectives in vaccine innovation.

Guest Editors

Dr. Valentina Di Salvatore

Department of Drug Sciences, Università degli Studi di Catania, Catania, Italy

Dr. Giulia Russo

Department of Drug Sciences, Università degli Studi di Catania, Catania, Italy

Deadline for manuscript submissions

31 July 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/254506

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).